Last updated 2026-07-20
- Raised Undisclosed Round led by HCS Capital, Feb 2022
Total raised
—
Last: Undisclosed Round 2022-03
Stage
Seed
Founded
2022
Headcount
7
HQ
Ramat Gan, Israel
Sector
Health Tech & Life Sciences
About
RenoVate Therapeutics is an early-stage biotechnology company based on research conducted by Prof. Benjamin Dekel at Sheba Medical Center, Israel. The company is developing regenerative biomolecules aimed at repairing and rejuvenating kidneys, with the goal of preventing the need for dialysis and kidney transplantations. Their lead product, KOSEC01, is a secretome-based drug derived from a proprietary 3D culture of kidney OrganoSpheroids, designed to treat all Chronic Kidney Disease (CKD) patients regardless of the underlying cause. RenoVate Therapeutics aims to halt fibrosis and prevent progression to end-stage renal failure.
Funding history · 1 round · — total
2022-02
Undisclosed Round
Undisclosed
★ HCS Capital
Headcount over time
From 4 (2023-02) to 7 (2025-10) · +3 (+75%) · 8 points · source: Finder history + radar grounding
Q&A
- What is RenoVate Therapeutics' primary focus?
- RenoVate Therapeutics is developing regenerative biomolecules to repair and rejuvenate kidneys, utilizing proprietary technology to expand cells from a patient's own urine.
- When was RenoVate Therapeutics founded?
- RenoVate Therapeutics was founded in February 2022.
- What is the current employee count for RenoVate Therapeutics?
- RenoVate Therapeutics has 1-10 employees.
- Which sector does RenoVate Therapeutics primarily operate in?
- RenoVate Therapeutics primarily operates in the Health Tech & Life Sciences sector.
- What is RenoVate Therapeutics' current product stage?
- RenoVate Therapeutics is currently in the R&D product stage.
- What was RenoVate Therapeutics' last funding event?
- In March 2022, RenoVate Therapeutics secured a funding round with.
- What is RenoVate Therapeutics' current funding stage?
- RenoVate Therapeutics is currently in the Seed funding stage.
Team · 4
Keren Souffir
Founder · Co-founder & CEO
Prof. Benjamin Dekel
Founder · Co-founder & Chief Scientist
Dr. Dorit Omer
Founder · Co-founder & CTO
Dr. David C. Pulver
Founder · Co-founder & Chairman
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesHealthcareProvidersPatientsLife SciencesBiotechnology
Business model
B2C
Tags
biotechnologynephrologydialysispharmaceuticals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | renovate.bio |
|---|---|
| linkedin.com/company/86758903 |
Identifiers & details
| Founded | 2022 |
|---|---|
| Employees (exact) | 7 |
Radar intelligence
Web history (Wayback)
| Domain | renovate.bio |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516566841 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2022-02-21 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 5 — shares_capital (2), people (1), other (1), annual_report (1) |
| Registered address | אהוד מנור 22 רעננה |
Recent registry events
| Date | Event |
|---|---|
| 2025-09-25 | העברת מניות |
| 2026-01-21 | עדכון דירקטורים-הסרת דירקטור |
| 2026-06-17 | הקצאת מניות |
| 2025-10-15 | שינוי בתקנון |
| 2025-08-04 | דו~ח שנתי |